Choroid plexus biomarkers capture neuroinflammatory processes associated with amyloid and neurodegeneration in Alzheimer's disease
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · 2026-10 · 18 (4)
DOI: 10.1002/dad2.70491 ↗Abstract
Abstract INTRODUCTION The amyloid/tau/neurodegeneration (ATN) framework characterizes Alzheimer's disease (AD) biomarkers but does not fully capture neuroinflammation. The choroid plexus (CP), a critical blood–cerebrospinal fluid (CSF) barrier component, has emerged as a neuroinflammatory imaging marker whose relationship to established AD biomarkers remains unclear. METHODS We analyzed multimodal data from 641 Alzheimer's Disease Neuroimaging Initiative participants using magnetic resonance imaging, amyloid/tau positron emission tomography, CSF/plasma biomarkers, and cognitive measures. Associations were examined via correlations, amyloid‐stratified analyses, and structural equation modeling (SEM). RESULTS CP volume was consistently associated with hippocampal atrophy but did not differentiate amyloid‐positive from amyloid‐negative individuals. Plasma glial fibrillary acidic protein showed the strongest association with CP volume, particularly in amyloid‐positive participants. SEM linked CP volume and entorhinal tau to hippocampal atrophy, with amyloid contributing indirectly through tau. DISCUSSION CP volume reflects neuroinflammatory processes more closely tied to neurodegeneration than to amyloid or tau pathology, supporting its role as a complementary biomarker within the ATN framework.
EUVIMED